Literature DB >> 11290327

Structural mechanism for rifampicin inhibition of bacterial rna polymerase.

E A Campbell1, N Korzheva, A Mustaev, K Murakami, S Nair, A Goldfarb, S A Darst.   

Abstract

Rifampicin (Rif) is one of the most potent and broad spectrum antibiotics against bacterial pathogens and is a key component of anti-tuberculosis therapy, stemming from its inhibition of the bacterial RNA polymerase (RNAP). We determined the crystal structure of Thermus aquaticus core RNAP complexed with Rif. The inhibitor binds in a pocket of the RNAP beta subunit deep within the DNA/RNA channel, but more than 12 A away from the active site. The structure, combined with biochemical results, explains the effects of Rif on RNAP function and indicates that the inhibitor acts by directly blocking the path of the elongating RNA when the transcript becomes 2 to 3 nt in length.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11290327     DOI: 10.1016/s0092-8674(01)00286-0

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  428 in total

1.  Translocation after synthesis of a four-nucleotide RNA commits RNA polymerase II to promoter escape.

Authors:  Jennifer F Kugel; James A Goodrich
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

2.  Modulation of DNA repair by mutations flanking the DNA channel through RNA polymerase.

Authors:  Brigitte W Trautinger; Robert G Lloyd
Journal:  EMBO J       Date:  2002-12-16       Impact factor: 11.598

Review 3.  The challenge of new drug discovery for tuberculosis.

Authors:  Anil Koul; Eric Arnoult; Nacer Lounis; Jerome Guillemont; Koen Andries
Journal:  Nature       Date:  2011-01-27       Impact factor: 49.962

4.  Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux.

Authors:  Gail E Louw; Robin M Warren; Nicolaas C Gey van Pittius; Rosalba Leon; Adelina Jimenez; Rogelio Hernandez-Pando; Christopher R E McEvoy; Melanie Grobbelaar; Megan Murray; Paul D van Helden; Thomas C Victor
Journal:  Am J Respir Crit Care Med       Date:  2011-04-21       Impact factor: 21.405

5.  RNA polymerase mutations that impair conversion to a termination-resistant complex by Q antiterminator proteins.

Authors:  Thomas J Santangelo; Rachel Anne Mooney; Robert Landick; Jeffrey W Roberts
Journal:  Genes Dev       Date:  2003-05-15       Impact factor: 11.361

6.  Global RNA half-life analysis in Escherichia coli reveals positional patterns of transcript degradation.

Authors:  Douglas W Selinger; Rini Mukherjee Saxena; Kevin J Cheung; George M Church; Carsten Rosenow
Journal:  Genome Res       Date:  2003-02       Impact factor: 9.043

7.  Nonthermal ATP-dependent fluctuations contribute to the in vivo motion of chromosomal loci.

Authors:  Stephanie C Weber; Andrew J Spakowitz; Julie A Theriot
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-19       Impact factor: 11.205

8.  Response to Klyuyev and Vassylyev: on the mechanism of tagetitoxin inhibition of transcription.

Authors:  Vladimir Svetlov; Irina Artsimovitch; Evgeny Nudler
Journal:  Transcription       Date:  2012-03-01

9.  Influence of DNA template choice on transcription and inhibition of Escherichia coli RNA polymerase.

Authors:  Joerg Haupenthal; Kristina Hüsecken; Matthias Negri; Christine K Maurer; Rolf W Hartmann
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

10.  Interaction of CarD with RNA polymerase mediates Mycobacterium tuberculosis viability, rifampin resistance, and pathogenesis.

Authors:  Leslie A Weiss; Phillip G Harrison; Bryce E Nickels; Michael S Glickman; Elizabeth A Campbell; Seth A Darst; Christina L Stallings
Journal:  J Bacteriol       Date:  2012-08-17       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.